Shikonin suppresses progression and epithelial mesenchymal transition in hepatocellular carcinoma (HCC) cells via modulating miR-106b/SMAD7/TGF- β signaling pathway.

In conclusion, Shikonin suppresses cell progression and EMT and accelerates cell death of HCC cells via modulating miR-106b/SMAD7/TGF-β signaling pathway, suggesting shikonin could be an effective agent for HCC treatment. This article is protected by copyright. All rights reserved. PMID: 31617643 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31617643?dopt=Abstract

Source: Cell Biology International - October 15, 2019 Category: Cytology Authors: Li X, Zeng X Tags: Cell Biol Int Source Type: research